Crossmark

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis

Crossref DOI link: https://doi.org/10.1016/j.aohep.2020.09.012

Published Print: 2021-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Zhuang, Liwei

Li, Junnan

Zhang, Yu

Ji, Shibo

Li, Yue

Zhao, Yingying

Li, Ben

Li, Wei

Quan, Min

Duan, Ying

Zhao, Hong

Cheng, Danying

Wang, Xiaomei

Ou, Weini

Xing, Huichun http://orcid.org/0000-0002-9111-9669
Funding

Funding for this research was provided by:

National Science and Technology Major Project of China under Gran (2018ZX10302-206-003-006)

Capital’s Funds for Health Improvement and Research (CFH 2020-1-2171, CFH 2018-2-2173)

Beijing Hospitals Authority Clinical Medicine Development of Special Funding (XMLX201837)

Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXT26)
License Information

Text and Data Mining valid from 2021-07-01

Text and Data Mining valid from 2021-07-01

Version of Record valid from 2020-10-06
More Information

This article is maintained by: Elsevier

Article Title: Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2020.09.012

Content Type: article

Copyright: © 2020 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C.

Document is current

Any future updates will be listed below